Every material Form 8-K ACCENDRA HEALTH INC/VA/ has filed with the SEC since November 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Accendra Health reported third quarter 2026 net revenue of $601.8 million, down from $697.3 million a year earlier, and adjusted EBITDA of $47.8 million, down from $92.2 million. The company said full-year net revenue will be at the bottom of its prior $2.45 billion to $2.55 billion range, and adjusted EBITDA could be as much as 30% below the $310 million midpoint of that outlook, which weighs on shareholders.
Q3 2026 net revenue was $601.8 million versus $697.3 million in Q3 2025.
Q3 2026 loss from continuing operations was $18.0 million, or $0.23 per share, versus a loss of $5.6 million, or $0.07 per share, a year earlier.
Full-year 2026 net revenue expected at the bottom of the prior $2.45 billion to $2.55 billion outlook range.
Adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of the prior outlook; CEO Kenny Gardner-Smith said 2026 results 'have fallen well short of our expectations.'
Accendra Health's Executive Vice President and Chief Operating Officer, Perry Bernocchi, will cease to be an executive officer under a transition agreement dated October 29, 2026, and serve as Strategic Advisor to the CEO until December 31, 2026, unless his employment ends earlier. He keeps his current base salary and remains eligible for his 2026 annual bonus at target and for applicable severance, which matters to shareholders as a senior operating leadership change.
Perry A. Bernocchi, EVP and Chief Operating Officer, ceases to be an executive officer under agreement dated October 29, 2026
Serves as Strategic Advisor to the Chief Executive Officer until December 31, 2026, unless employment ends earlier
Keeps current base salary and remains eligible for 2026 annual bonus at current target
Remains eligible for severance under Officer Severance Policy or change of control agreement, as applicable
Accendra Health's subsidiaries amended their receivables purchase agreement with PNC Bank, extending the scheduled termination date to October 2029. The $150 million program size is unchanged, and the company says the extension supports its liquidity. The filing does not disclose financial results or a cost of the amendment.
Third Amendment to the receivables purchase agreement was signed October 29, 2026
Scheduled Termination Date extended to October 2029; $150 million facility size unchanged
Revised account control provisions and reporting obligations; PNC Bank is administrative agent
Full amendment to be filed as an exhibit to the 2026 Form 10-K
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ACCENDRA HEALTH INC/VA/ filing is on SEC EDGAR ↗. 8-K briefs of other companies →